Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 8/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 6/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 3/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 1.00 |
| ▸ | NCOR1 | O75376 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | NAMPT | P43490 | 6/20 | 0.86 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8057949 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL30267913 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Tucidinostat SCHEMBL13815849 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Tucidinostat SCHEMBL29350211 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Tucidinostat SCHEMBL4483082 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| Tucidinostat SCHEMBL29813059 | 0.93 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6842697 | 0.89 | HDAC1 (0.85) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6842698 | 0.89 | HDAC1 (0.85) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL17153995 | 0.88 | HDAC1 (0.79) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL16892137 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697674-B2 | Human chorionic gonadotropin variant peptides and treatment of breast cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2023-07-11 | — | — | US | claimed |
| US-20210188935-A1 | HUMAN CHORIONIC GONADOTROPIN VARIANT PEPTIDES AND TREATMENT OF BREAST CANCER | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2021-06-24 | — | — | US | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | disclosed |
| US-20240285556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | OHIO STATE INNOVATION FOUNDATION | 2024-08-29 | — | — | US | disclosed |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-9573901-B2 | Crystal form of chidamide, preparation method and use thereof | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2017-02-21 | — | — | US | disclosed |
| US-20150299126-A1 | CRYSTAL FORM OF CHIDAMIDE, PREPARATION METHOD AND USE THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2930169-A1 | CRYSTAL FORM OF CHIDAMIDE, PREPARATION METHOD AND USE THEREOF | Shenzhen Chipscreen Biosciences, Ltd. (CN) | 2015-10-14 | — | — | EP | disclosed |
| EP-2860174-A2 | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation acivity | Shenzhen Chipscreen Biosciences Ltd. (CN) | 2015-04-15 | — | — | EP | disclosed |
| EP-1592665-A4 | HISTONE DEACETYLASE INHIBITORS OF NOVEL BENZAMIDE DERIVATIVES WITH POTENT DIFFERENTIATION AND ANTI-PROLIFERATION ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCE (CN) | 2007-07-18 | — | — | EP | disclosed |
| EP-1592665-A2 | HISTONE DEACETYLASE INHIBITORS OF NOVEL BENZAMIDE DERIVATIVES WITH POTENT DIFFERENTIATION AND ANTI-PROLIFERATION ACTIVITY | Shenzhen Chipscreen Biosciences Ltd. (CN) | 2005-11-09 | — | — | EP | disclosed |
| US-20040224991-A1 | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-11-11 | — | — | US | disclosed |
| WO-2004071400-A2 | HISTONE DEACETYLASE INHIBITORS OF NOVEL BENZAMIDE DERIVATIVES WITH POTENT DIFFERENTIATION AND ANTI-PROLIFERATION ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | HDAC1 3531/4885HDAC2 2063/4885HDAC3 3869/4885 |
| US-20150299126-A1 | CRYSTAL FORM OF CHIDAMIDE, PREPARATION METHOD AND USE THEREOF | CHIA, CRYAB, CYP21A2 | HDAC1 49/4885HDAC2 122/4885HDAC3 45/4885 |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | HDAC1 985/4885HDAC2 861/4885HDAC3 427/4885 |
| US-20040224991-A1 | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC2 7/4885HDAC3 12/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | HDAC1 463/4885HDAC2 473/4885HDAC3 129/4885 |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | HDAC1 249/4885HDAC2 164/4885HDAC3 173/4885 |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | AVPR2, RXFP3, OPRD1 | HDAC1 480/4885HDAC2 291/4885HDAC3 158/4885 |
| US-20240285556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | HDAC5, HDAC1, HDAC7 | HDAC1 2/4885HDAC2 5/4885HDAC3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.